| 영문 | carcinoembryonic antigen | 한글 | 암배아항원 |
|---|---|---|---|
| 설명 | 원래 태아의 장조직에서 정상적으로 존재하는 물질로 태아기 이후에는 존재하지 않는 물질이다. 그러나 위, 간, 허파 등의 암이 있는 경우에 성인에서도 존재한다. 이를 이용해서 암의 치료효과 판정이나 재발여부의 조사에 이용한다. |
||
| 영문 | antigen | 한글 | 항원 |
|---|---|---|---|
| 설명 | 특이한 면역반응을 일으킬 수 있는 어떠한 물질. 여기에서 말하는 특이한 면역반응이란 비특이적인 면역반응과는 반대되는 의미로 그 물질에 대해서 특이하게 반응할 수 있는 항체나 그 물질에 대해서 특이하게 반응할 수 있는 세포를 만드는 것을 말한다. |
||
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| Bmod | behavior modification |
| CM | California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ... |
| DMF | Dose modification factors |
|---|---|
| ICD9CM | International Classification of Diseases 9th Revision Clinical Modification |
| ICD-9 CM | International Classification of Diseases, Ninth Revision, Clinical Modification |
| MDRD | Modification of Diet in Renal Disease |
| R-M | Restriction and modification |
| modification | 1. A nonhereditary change in an organism; e.g., one that is acquired from its own activity or environment. 2. A chemical or structural alteration in a molecule. Behaviour modification, the systematic use of principles of conditioning and learning, especially operant or instrumental conditioning, to teach certain skills or to extinguish undesirable behaviours, attitudes, or phobias. Chemical modification, alteration in the structure of a molecule, typically a macromolecule such as a protein, by chemical means; often, the covalent addition by some reagent. Covalent modification, alteration in the structure of a macromolecule by enzymatic means, resulting in a change in the properties of that macromolecule; frequently, this type of modification is physiologically relevant. (05 Mar 2000) |
|---|---|
| modification enzyme | <enzyme, molecular biology> An enzyme that introduces minor bases into DNA or RNA or that alters bases already incorporated. Serves to alter the sequence so that restriction enzymes will not damage the strand. (18 Nov 1997) |
| post-translational modification | The enzymatic processing of a polypeptide chain after translation from messenger RNA and after peptide bond formation has occurred. Examples include glycosylation, acylation, limited proteolysis, phosphorylation, isoprenylation. (10 Oct 1997) |
| ScrFI modification methylase | <enzyme> From lactococcus lactis subsp. Cremoris uc503; recognises sequence ccngg and forms m(5)ccngg; see also DNA modification methylase dsav and DNA modification methylase ssoii Registry number: EC 2.1.1.- Synonym: scrfi methylase (26 Jun 1999) |
| host restriction-modification | A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it. (09 Oct 1997) |
| Stirling's modification of Gram's stain | <technique> A stable aniline-crystal violet stain. (05 Mar 2000) |
| DNA modification | <molecular biology> A variety of chemical changes made to a DNA molecule just after it has been replicated. An example is DNA methylation. (09 Oct 1997) |
| DNA modification methylases | <enzyme> Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the hosT-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognised by the restriction endonucleases of similar specificity and destroyed by cleavage. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. Registry number: EC 2.1.1.- (12 Dec 1998) |
| DNA restriction-modification enzymes | Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage. (12 Dec 1998) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|